Skip to content

Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation

A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01078818
Enrollment
159
Registered
2010-03-02
Start date
2007-05-31
Completion date
2009-05-31
Last updated
2010-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia

Keywords

Cardiac surgery, Extracorporeal circulation, Anaemia, Intravenous iron, Oral Iron

Brief summary

Anaemia is a common postoperative problem of cardiovascular surgery after cardiopulmonary bypass (CPB). Because of this the need for hemoderived blood transfusions is high. The purpose of this study was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact of the iron on the transfusion rate in postoperative cardiovascular surgery under extracorporeal circulation.

Detailed description

Prospective double dummy triple blind study of 159 patients undergoing CPB; randomised in 3 groups treated with iron intravenously (iv) (group I), with iron orally (group II) controlled with placebo (group III). Patients from group I were treated with iv Iron sucrose , three doses of 100 mg of iv iron every 24 hours during postoperative hospitalization and 1 pill/24 h of oral placebo during the first month after discharge. Group II was programmed to receive 1 iron pill orally every 24 hours pre and postoperatively and up to one month after discharge and a placebo while hospitalized. Group III was programmed to receive an oral and iv placebo pre and postoperatively. Variables were collected preoperatively, at operation room and at Intensive Care Unit admission and discharge, at postoperative floor discharge and at one month after surgical discharge.

Interventions

DRUGIV trivalent saccharose hydroxide ferrous

Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up 1 month 1 oral placebo /24h

200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) Postoperative Period: 200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet

DRUGOral and intravenous Placebo

Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h

Sponsors

Fundación Canaria Rafael Clavijo para la Investigación Biomédica
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 78 Years
Healthy volunteers
No

Inclusion criteria

* Men and women ≥ 18 years of age * Patients subject to elective cardiac surgery under extracorporeal circulation * Patients without previous anaemia, susceptible of treatment * Patients without need of blood transfusion preoperative * Patients providing written informed consent * Patients who are able to complete all study visits per protocol

Exclusion criteria

* Patients subject to elective cardiac surgery, but without extracorporeal circulation * Patients who were treated with fibrinolytic therapy 48 hours before the surgery * Patients with history of impaired renal function, (e.g., calculated creatinine clearance \<50 mL/min/1.73 m2) * Patients operated of active endocarditis * Redo-surgery patients * Women who are pregnant or lactating * Patients with clinical of digestive bleeding * Patients with vitamin B12 deficit * Patients with ferropenic anaemia * Patients with clinical history of asthma or allergy * Patients with active infection * Patients who are included in another clinical study * Patients with hepatic disease * Patients with history of allergy to iron * Patients unlikely to adhere to protocol follow-up

Design outcomes

Primary

MeasureTime frameDescription
Haemoglobin and Hematocrit values2 yearsThe objective was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact on the transfusion rate needing in Cardiovascular surgery under cardiopulmonary bypass

Secondary

MeasureTime frameDescription
need for hemoderived blood transfusions, postoperative stay and hospital costs2 yearsThe objective was to compare the clinical efficacy of intravenous and oral iron in anaemia and the impact on the transfusion rate needing in Cardiovascular surgery under cardiopulmonary bypass

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026